AngioDynamics, Inc. (NASDAQ:ANGO) Short Interest Update

AngioDynamics, Inc. (NASDAQ:ANGO - Get Free Report) was the recipient of a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 1,230,000 shares, a decline of 16.9% from the October 15th total of 1,480,000 shares. Based on an average daily trading volume, of 479,100 shares, the short-interest ratio is presently 2.6 days.

Analyst Upgrades and Downgrades

ANGO has been the subject of a number of recent analyst reports. HC Wainwright reissued a "buy" rating and set a $14.00 target price on shares of AngioDynamics in a research report on Friday, October 4th. Canaccord Genuity Group reduced their price target on shares of AngioDynamics from $13.00 to $12.00 and set a "buy" rating for the company in a research report on Friday, October 4th.

Insider Buying and Selling at AngioDynamics

In other AngioDynamics news, CEO James C. Clemmer bought 20,000 shares of the firm's stock in a transaction on Monday, October 7th. The shares were purchased at an average price of $6.03 per share, for a total transaction of $120,600.00. Following the completion of the transaction, the chief executive officer now directly owns 681,582 shares in the company, valued at approximately $4,109,939.46. The trade was a 3.02 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. In the last three months, insiders have acquired 22,568 shares of company stock worth $135,847. Insiders own 5.40% of the company's stock.

Hedge Funds Weigh In On AngioDynamics

A number of hedge funds have recently modified their holdings of the company. Segall Bryant & Hamill LLC grew its stake in AngioDynamics by 142.7% in the third quarter. Segall Bryant & Hamill LLC now owns 911,443 shares of the medical instruments supplier's stock worth $7,091,000 after purchasing an additional 535,958 shares during the period. Millennium Management LLC increased its position in shares of AngioDynamics by 41.9% during the second quarter. Millennium Management LLC now owns 1,793,454 shares of the medical instruments supplier's stock valued at $10,850,000 after acquiring an additional 529,861 shares in the last quarter. Western Standard LLC raised its stake in shares of AngioDynamics by 878.5% in the first quarter. Western Standard LLC now owns 523,393 shares of the medical instruments supplier's stock worth $3,072,000 after purchasing an additional 469,906 shares during the last quarter. First Eagle Investment Management LLC bought a new position in shares of AngioDynamics during the second quarter valued at $1,321,000. Finally, Systematic Financial Management LP raised its position in AngioDynamics by 8.4% in the 2nd quarter. Systematic Financial Management LP now owns 2,109,561 shares of the medical instruments supplier's stock worth $12,763,000 after buying an additional 162,972 shares during the last quarter. Hedge funds and other institutional investors own 89.43% of the company's stock.

AngioDynamics Trading Down 0.7 %

Shares of NASDAQ:ANGO traded down $0.05 during mid-day trading on Friday, reaching $6.80. The company had a trading volume of 170,125 shares, compared to its average volume of 527,426. AngioDynamics has a one year low of $5.26 and a one year high of $8.25. The company's 50-day moving average price is $7.02 and its 200-day moving average price is $6.75.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last announced its quarterly earnings data on Thursday, October 3rd. The medical instruments supplier reported ($0.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.04. The business had revenue of $67.50 million for the quarter, compared to analysts' expectations of $67.93 million. AngioDynamics had a negative return on equity of 5.86% and a negative net margin of 83.95%. The firm's quarterly revenue was down 14.2% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.12) EPS. Sell-side analysts expect that AngioDynamics will post -0.41 earnings per share for the current year.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.